Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Robert M, Conry"'
Autor:
Timothy G. Norwood, Carrie A. Lenneman, MD, Brian C. Westbrook, Silvio H. Litovsky, MD, Svetlana B. McKee, RN, BSN, Robert M. Conry, MD
Publikováno v:
JACC: Case Reports, Vol 2, Iss 2, Pp 203-209 (2020)
Ipilimumab and nivolumab for melanoma induced smoldering myocarditis remitting with steroids. Rechallenge with nivolumab produced steroid-refractory myocarditis confirmed by electron microscopy. Tacrolimus and mycophenolate transiently reduced inflam
Externí odkaz:
https://doaj.org/article/5defb6f3435e4bbeb14a04c093d865bb
Autor:
Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark A. Taylor, Madhuri Bajaj, Robert M. Conry, Robert J. Ellis, Theodore F. Logan, Noel Laudi, Jeffrey A. Sosman, David G. Crockett, Andrew L. Pecora, Ian J. Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X. Chen, Howard Z. Streicher, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 41:186-197
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b1385a7ab421246b7bc70886ef74c7
https://doi.org/10.1200/jco.22.01763
https://doi.org/10.1200/jco.22.01763
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 4, Pp 839-846 (2018)
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor
Externí odkaz:
https://doaj.org/article/172bca9a486f445f982ae8b7cae59050
Autor:
Timothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L. Terry, Svetlana B. McKee, Alan S. Gertler, Javid J. Moslehi, Robert M. Conry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-6 (2017)
Abstract Background Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of less than 1%. Howeve
Externí odkaz:
https://doaj.org/article/954f4ac729624cc49ee9c4c13eb10484
Autor:
Jonathan T. Blackmon, Michael S. Stratton, MD, Young Kwak, MD, Peter G. Pavlidakey, MD, Andrzej T. Slominski, MD, Svetlana B. McKee, RN, BSN, Toni M. Viator, RN, Ju Young Kim, PhD, Conway C. Huang, MD, Robert M. Conry, MD
Publikováno v:
JAAD Case Reports, Vol 3, Iss 4, Pp 280-283 (2017)
Externí odkaz:
https://doaj.org/article/9c7d8758102c4169a6e9450ef66bd8d3
Autor:
Jonathan T. Blackmon, Ratika Dhawan, MBBS, MPH, Toni M. Viator, RN, Nina L. Terry, MD, JD, Robert M. Conry, MD
Publikováno v:
JAAD Case Reports, Vol 3, Iss 3, Pp 185-189 (2017)
Externí odkaz:
https://doaj.org/article/17c56c06616340dfbffbe160641dff0b
Publikováno v:
Radiology Case Reports, Vol 13, Iss 1, Pp 89-91 (2018)
Immune checkpoint blockade (CPB) utilizing such agents as ipilimumab, nivolumab, or pembrolizumab has revolutionized melanoma therapy and has seen continued utilization in numerous other malignancies in recent years. However, these agents come at the
Externí odkaz:
https://doaj.org/article/16cccb632a254464bfe21d712d8dd2fc
Autor:
Daniel Y Wang, Meghan J Mooradian, DaeWon Kim, Neil J Shah, Sarah E Fenton, Robert M Conry, Rutika Mehta, Ann W. Silk, Alice Zhou, Margaret L Compton, Rami N Al-Rohil, Sunyoung Lee, Amber L Voorhees, Lisa Ha, Svetlana McKee, Jacqueline T Norrell, Janice Mehnert, Igor Puzanov, Jeffrey A Sosman, Sunandana Chandra, Geoffrey T Gibney, Suthee Rapisuwon, Zeynep Eroglu, Ryan Sullivan, Douglas B Johnson
Publikováno v:
OncoImmunology, Vol 8, Iss 1 (2019)
Colitis is a frequent, clinically-significant immune-related adverse event caused by anti-programmed death-1 (PD-1). The clinical features, timing, and management of colitis with anti-PD-1-based regimens are not well-characterized. Patients with adva
Externí odkaz:
https://doaj.org/article/47c6c7c86d354dbcaa13aa6907596ec4
Autor:
Antoni Ribas, John M. Kirkwood, Larissa A. Korde, Elad Sharon, Nageatte Ibrahim, Sama Ahsan, Scot W. Ebbinghaus, Krishna S. Gunturu, Magdalena Kovacsovics-Bankowski, Brian Gastman, Zeynep Eroglu, James Moon, Hongli Li, Douglas B. Johnson, Ragini R. Kudchadkar, Bartosz Chmielowski, Robert M. Conry, Karl D. Lewis, Pauline Funchain, Kari Kendra, Elizabeth I. Buchbinder, Justine V. Cohen, Nikhil I. Khushalani, Thach-Giao Truong, Teresa M. Petrella, Michael V. Knopp, Vernon K. Sondak, Ahmad A. Tarhini, Sapna P. Patel, Megan Othus, Kenneth F. Grossmann
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70860ad8a591df39f1504fb8bc1ae75a
https://doi.org/10.1158/2159-8290.22541236.v1
https://doi.org/10.1158/2159-8290.22541236.v1
Autor:
John M. Kirkwood, Ahmad A. Tarhini, Robert M. Conry, Dean A. Jobe, Steven M. Callister, Donghoon Shin, Sandra J. Lee, Ronald S. Go
Purpose: We investigated the use of graded-dose peginterferon α-2b (Peg-IFN) in patients with stage IV melanoma overexpressing basic fibroblast growth factor (FGF-2). The primary objective was suppression of plasma FGF-2 to within reference range (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e519fa2039b6c0e979334075bec5b50
https://doi.org/10.1158/1078-0432.c.6521790.v1
https://doi.org/10.1158/1078-0432.c.6521790.v1